COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement

McCaughan, G; Di Ciaccio, P; Ananda-Rajah, M; Gilroy, N; MacIntyre, R; Teh, B; Weinkove, R; Curnow, J; Szer, J; Enjeti, AK; Ross, DM; Mulligan, S; Trotman, J; Dickinson, M; Quach, H; Choi, P; Polizzotto, MN; Tam, CS; Ho, PJ; Ku, M; Gregory, G; Gangatharan, S; Hapgood, G; Cochrane, T; Cheah, C; Gibbs, S; Wei, A; Johnston, A; Greenwood, M; Prince, HM; Latimer, M; Berkahn, L; Wight, J; Armytage, T; Hamad, N

eCite Digital Repository

COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement

Citation

McCaughan, G and Di Ciaccio, P and Ananda-Rajah, M and Gilroy, N and MacIntyre, R and Teh, B and Weinkove, R and Curnow, J and Szer, J and Enjeti, AK and Ross, DM and Mulligan, S and Trotman, J and Dickinson, M and Quach, H and Choi, P and Polizzotto, MN and Tam, CS and Ho, PJ and Ku, M and Gregory, G and Gangatharan, S and Hapgood, G and Cochrane, T and Cheah, C and Gibbs, S and Wei, A and Johnston, A and Greenwood, M and Prince, HM and Latimer, M and Berkahn, L and Wight, J and Armytage, T and Hamad, N, COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement, Internal Medicine Journal, 51, (5) pp. 763-768. ISSN 1444-0903 (2021) [Refereed Article]

Copyright Statement

DOI: doi:10.1111/imj.15247

Abstract

Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID-19 vaccination in patients with haematological disorders. It is our recommendation that patients with haematological malignancies, and some benign haematological disorders, should have expedited access to high-efficacy COVID-19 vaccines, given that these patients are at high risk of morbidity and mortality from COVID-19 infection. Vaccination should not replace other public health measures in these patients, given that the effectiveness of COVID-19 vaccination, specifically in patients with haematological malignancies, is not known. Given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.

Item Details

Item Type:	Refereed Article
Research Division:	Biomedical and Clinical Sciences
Research Group:	Cardiovascular medicine and haematology
Research Field:	Respiratory diseases
Objective Division:	Health
Objective Group:	Clinical health
Objective Field:	Treatment of human diseases and conditions
UTAS Author:	Johnston, A (Dr Anna Johnston)
ID Code:	146865
Year Published:	2021
Web of Science^® Times Cited:	2
Deposited By:	Medicine
Deposited On:	2021-09-30
Last Modified:	2021-10-19
Downloads:	0

Repository Staff Only: item control page